Europe Diabetic Neuropathy Treatment Market Size, Share & Trends Analysis Report By Distribution Channel, By Drug Class, By Disorder Type, By Country and Growth Forecast, 2024

List of Tables

The Europe Diabetic Neuropathy Treatment Market would witness market growth of 6.9% CAGR during the forecast period (2024-2031).

The Germany market dominated the Europe Diabetic Neuropathy Treatment Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $454 million by 2031. The UK market is exhibiting a CAGR of 6% during (2024 - 2031). Additionally, The France market would experience a CAGR of 7.8% during (2024 - 2031).

As the condition's prevalence rises and the need for effective therapeutic interventions intensifies, the market for it is undergoing a rapid evolution. In recent years, there have been significant advancements in the understanding of this and the development of new treatment options.

Additionally, due to these developments, the management of this has shifted to place more importance on early detection and intervention to impede or halt the progression of nerve damage.

European research and innovation efforts contribute to developing novel and more effective treatment modalities for diabetic neuropathy. This includes discovering new pharmacological agents, biotechnological therapies, and medical devices specifically designed to target neuropathic symptoms. According to the European Commission, research and innovation on diabetes and related factors, such as obesity, has been a longstanding priority for the EU. Over EUR 1.25 billion has been devoted to support research in the last decade.

Based on Distribution Channel, the market is segmented into Hospitals Pharmacies, Retail Pharmacies and Others. Based on Drug Class, the market is segmented into Non-Steroidal Anti-inflammatory Drugs (NSAIDs), Antidepressants, Opioid, Capsaicin and Others. Based on Disorder Type, the market is segmented into Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy and Focal Neuropathy. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

List of Key Companies Profiled

Abbott Laboratories
Eli Lilly And Company
Pfizer, Inc.
Lupin Limited
Astellas Pharma, Inc.
Glenmark Pharmaceuticals Limited
Boehringer Ingelheim International GmbH
Novartis AG
McKesson Corporation
GlaxoSmithKline PLC (GSK)

Europe Diabetic Neuropathy Treatment Market Report Segmentation

By Distribution Channel

Hospitals Pharmacies
Retail Pharmacies
Others

By Drug Class

Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
Antidepressants
Opioid
Capsaicin
Others

By Disorder Type

Peripheral Neuropathy
Autonomic Neuropathy
Proximal Neuropathy
Focal Neuropathy

By Country

Germany
UK
France
Russia
Spain
Italy
Rest of Europe

Chapter 1.Market Scope & Methodology

1.1Market Definition
1.2Objectives
1.3Market Scope
1.4Segmentation
- 1.4.1Europe Diabetic Neuropathy Treatment Market, by Distribution Channel
- 1.4.2Europe Diabetic Neuropathy Treatment Market, by Drug Class
- 1.4.3Europe Diabetic Neuropathy Treatment Market, by Disorder Type
- 1.4.4Europe Diabetic Neuropathy Treatment Market, by Country
1.5Methodology for the research

Chapter 2.Market at a Glance

2.1Key Highlights

Chapter 3.Market Overview

3.1Introduction
- 3.1.1Overview
  - 3.1.1.1Market Composition and Scenario
3.2Key Factors Impacting the Market
- 3.2.1Market Drivers
- 3.2.2Market Restraints
- 3.2.3Market Opportunities
- 3.2.4Market Challenges
3.3Porter Five Forces Analysis

Chapter 4.Europe Diabetic Neuropathy Treatment Market by Distribution Channel

4.1Europe Hospitals Pharmacies Market by Country
4.2Europe Retail Pharmacies Market by Country
4.3Europe Others Market by Country

Chapter 5.Europe Diabetic Neuropathy Treatment Market by Drug Class

5.1Europe Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Market by Country
5.2Europe Antidepressants Market by Country
5.3Europe Opioid Market by Country
5.4Europe Capsaicin Market by Country
5.5Europe Others Market by Country

Chapter 6.Europe Diabetic Neuropathy Treatment Market by Disorder Type

6.1Europe Peripheral Neuropathy Market by Country
6.2Europe Autonomic Neuropathy Market by Country
6.3Europe Proximal Neuropathy Market by Country
6.4Europe Focal Neuropathy Market by Country

Chapter 7.Europe Diabetic Neuropathy Treatment Market by Country

7.1Germany Diabetic Neuropathy Treatment Market
- 7.1.1Germany Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.1.2Germany Diabetic Neuropathy Treatment Market by Drug Class
- 7.1.3Germany Diabetic Neuropathy Treatment Market by Disorder Type
7.2UK Diabetic Neuropathy Treatment Market
- 7.2.1UK Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.2.2UK Diabetic Neuropathy Treatment Market by Drug Class
- 7.2.3UK Diabetic Neuropathy Treatment Market by Disorder Type
7.3France Diabetic Neuropathy Treatment Market
- 7.3.1France Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.3.2France Diabetic Neuropathy Treatment Market by Drug Class
- 7.3.3France Diabetic Neuropathy Treatment Market by Disorder Type
7.4Russia Diabetic Neuropathy Treatment Market
- 7.4.1Russia Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.4.2Russia Diabetic Neuropathy Treatment Market by Drug Class
- 7.4.3Russia Diabetic Neuropathy Treatment Market by Disorder Type
7.5Spain Diabetic Neuropathy Treatment Market
- 7.5.1Spain Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.5.2Spain Diabetic Neuropathy Treatment Market by Drug Class
- 7.5.3Spain Diabetic Neuropathy Treatment Market by Disorder Type
7.6Italy Diabetic Neuropathy Treatment Market
- 7.6.1Italy Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.6.2Italy Diabetic Neuropathy Treatment Market by Drug Class
- 7.6.3Italy Diabetic Neuropathy Treatment Market by Disorder Type
7.7Rest of Europe Diabetic Neuropathy Treatment Market
- 7.7.1Rest of Europe Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.7.2Rest of Europe Diabetic Neuropathy Treatment Market by Drug Class
- 7.7.3Rest of Europe Diabetic Neuropathy Treatment Market by Disorder Type

Chapter 8.Company Profiles

8.1Abbott Laboratories
- 8.1.1Company Overview
- 8.1.2Financial Analysis
- 8.1.3Segmental and Regional Analysis
- 8.1.4Research & Development Expense
- 8.1.5Recent strategies and developments:
  - 8.1.5.1Acquisition and Mergers:
  - 8.1.5.2Trial and Approval:
- 8.1.6SWOT Analysis
8.2Eli Lilly And Company
- 8.2.1Company Overview
- 8.2.2Financial Analysis
- 8.2.3Regional Analysis
- 8.2.4Research & Development Expenses
- 8.2.5Recent strategies and developments:
  - 8.2.5.1Acquisition and Mergers:
- 8.2.6SWOT Analysis
8.3Pfizer, Inc.
- 8.3.1Company Overview
- 8.3.2Financial Analysis
- 8.3.3Regional & Segmental Analysis
- 8.3.4Research & Development Expense
- 8.3.5SWOT Analysis
8.4Lupin Limited
- 8.4.1Company Overview
- 8.4.2Financial Analysis
- 8.4.3Regional Analysis
- 8.4.4Research & Development Expense
- 8.4.5SWOT Analysis
8.5Astellas Pharma, Inc.
- 8.5.1Company Overview
- 8.5.2Financial Analysis
- 8.5.3Regional Analysis
- 8.5.4Research & Development Expense
- 8.5.5SWOT Analysis
8.6Glenmark Pharmaceuticals Limited
- 8.6.1Company Overview
- 8.6.2Financial Analysis
- 8.6.3Regional Analysis
- 8.6.4Research & Development Expenses
- 8.6.5SWOT Analysis
8.7Boehringer Ingelheim International GmbH
- 8.7.1Company Overview
- 8.7.2Financial Analysis
- 8.7.3Regional & Segmental Analysis
- 8.7.4Research & Development Expenses
- 8.7.5SWOT Analysis
8.8Novartis AG
- 8.8.1Company Overview
- 8.8.2Financial Analysis
- 8.8.3Segmental and Regional Analysis
- 8.8.4Research & Development Expense
- 8.8.5Recent strategies and developments:
  - 8.8.5.1Acquisition and Mergers:
- 8.8.6SWOT Analysis
8.9McKesson Corporation
- 8.9.1Company Overview
- 8.9.2Financial Analysis
- 8.9.3Segmental Analysis
- 8.9.4Research & Development Expense
- 8.9.5SWOT Analysis
8.10.GlaxoSmithKline PLC (GSK)
- 8.10.1Company Overview
- 8.10.2Financial Analysis
- 8.10.3Regional Analysis
- 8.10.4Research & Development Expense
- 8.10.5SWOT Analysis

LIST OF TABLES

TABLE 1Europe Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 2Europe Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 3Europe Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 4Europe Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 5Europe Hospitals Pharmacies Market by Country, 2020 - 2023, USD Million
TABLE 6Europe Hospitals Pharmacies Market by Country, 2024 - 2031, USD Million
TABLE 7Europe Retail Pharmacies Market by Country, 2020 - 2023, USD Million
TABLE 8Europe Retail Pharmacies Market by Country, 2024 - 2031, USD Million
TABLE 9Europe Others Market by Country, 2020 - 2023, USD Million
TABLE 10Europe Others Market by Country, 2024 - 2031, USD Million
TABLE 11Europe Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 12Europe Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 13Europe Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Market by Country, 2020 - 2023, USD Million
TABLE 14Europe Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Market by Country, 2024 - 2031, USD Million
TABLE 15Europe Antidepressants Market by Country, 2020 - 2023, USD Million
TABLE 16Europe Antidepressants Market by Country, 2024 - 2031, USD Million
TABLE 17Europe Opioid Market by Country, 2020 - 2023, USD Million
TABLE 18Europe Opioid Market by Country, 2024 - 2031, USD Million
TABLE 19Europe Capsaicin Market by Country, 2020 - 2023, USD Million
TABLE 20Europe Capsaicin Market by Country, 2024 - 2031, USD Million
TABLE 21Europe Others Market by Country, 2020 - 2023, USD Million
TABLE 22Europe Others Market by Country, 2024 - 2031, USD Million
TABLE 23Europe Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 24Europe Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 25Europe Peripheral Neuropathy Market by Country, 2020 - 2023, USD Million
TABLE 26Europe Peripheral Neuropathy Market by Country, 2024 - 2031, USD Million
TABLE 27Europe Autonomic Neuropathy Market by Country, 2020 - 2023, USD Million
TABLE 28Europe Autonomic Neuropathy Market by Country, 2024 - 2031, USD Million
TABLE 29Europe Proximal Neuropathy Market by Country, 2020 - 2023, USD Million
TABLE 30Europe Proximal Neuropathy Market by Country, 2024 - 2031, USD Million
TABLE 31Europe Focal Neuropathy Market by Country, 2020 - 2023, USD Million
TABLE 32Europe Focal Neuropathy Market by Country, 2024 - 2031, USD Million
TABLE 33Europe Diabetic Neuropathy Treatment Market by Country, 2020 - 2023, USD Million
TABLE 34Europe Diabetic Neuropathy Treatment Market by Country, 2024 - 2031, USD Million
TABLE 35Germany Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 36Germany Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 37Germany Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 38Germany Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 39Germany Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 40Germany Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 41Germany Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 42Germany Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 43UK Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 44UK Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 45UK Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 46UK Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 47UK Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 48UK Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 49UK Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 50UK Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 51France Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 52France Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 53France Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 54France Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 55France Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 56France Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 57France Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 58France Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 59Russia Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 60Russia Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 61Russia Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 62Russia Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 63Russia Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 64Russia Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 65Russia Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 66Russia Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 67Spain Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 68Spain Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 69Spain Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 70Spain Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 71Spain Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 72Spain Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 73Spain Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 74Spain Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 75Italy Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 76Italy Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 77Italy Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 78Italy Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 79Italy Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 80Italy Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 81Italy Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 82Italy Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 83Rest of Europe Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 84Rest of Europe Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 85Rest of Europe Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 86Rest of Europe Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 87Rest of Europe Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 88Rest of Europe Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 89Rest of Europe Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 90Rest of Europe Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 91Key Information - Abbott Laboratories
TABLE 92Key Information - Eli Lilly And Company
TABLE 93Key Information - Pfizer, Inc.
TABLE 94Key Information - Lupin Limited
TABLE 95key information - Astellas Pharma, Inc.
TABLE 96Key Information - Glenmark Pharmaceuticals Limited
TABLE 97Key Information - Boehringer Ingelheim International GmbH
TABLE 98Key Information - Novartis AG
TABLE 99Key Information - McKesson Corporation
TABLE 100Key Information - GlaxoSmithKline PLC

Europe Diabetic Neuropathy Treatment Market Size, Share & Trends Analysis Report By Distribution Channel, By Drug Class, By Disorder Type, By Country and Growth Forecast, 2024 - 2031

Description

Table of Contents